SCHEMBL6718240

SCHEMBL6718240

Cc1c(Cl)cccc1S(=O)(=O)Nc1cccc(C2=NCCc3ccccc32)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GSPT1 P15170 1/20 0.47
DDB1 Q16531 1/20 0.47
CRBN Q96SW2 1/20 0.47
HSD11B1 P28845 4/20 0.44
EDNRB P24530 2/20 0.42
EDNRA P25101 2/20 0.42
SYK P43405 1/20 0.41
MAPK10 P53779 4/20 0.41
SLC40A1 Q9NP59 1/20 0.40
PRMT6 Q96LA8 1/20 0.39
MAPT P10636 2/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
THRB P10828 1/20 0.39
ITGA1 P56199 1/20 0.39
WDR5 P61964 1/20 0.39
MAPK9 P45984 1/20 0.39
MAPK14 Q16539 1/20 0.39
PFKFB4 Q16877 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6716714 0.91 GSPT1 (0.45) GSPT1DDB1CRBNHSD11B1EDNRB
SCHEMBL6724930 0.90 GSPT1 (0.45) GSPT1DDB1CRBNHSD11B1EDNRB
SCHEMBL6716845 0.90 GSPT1 (0.46) GSPT1DDB1CRBNHSD11B1EDNRB
SCHEMBL6720515 0.89 MAPK10 (0.46) GSPT1DDB1CRBNHSD11B1EDNRB
SCHEMBL6720455 0.88 MAPK10 (0.46) GSPT1DDB1CRBNHSD11B1EDNRB
SCHEMBL6714790 0.86 LMNA (0.47) GSPT1DDB1CRBNHSD11B1SYK
SCHEMBL6720563 0.83 PFKFB3 (0.55) MAPK10MAPTLMNATP53THRB
SCHEMBL6724595 0.83 GSPT1 (0.44) GSPT1DDB1CRBNHSD11B1EDNRB
SCHEMBL6720416 0.81 EDNRA (0.53) EDNRASYK
SCHEMBL6716447 0.81 CDK1 (0.49) SYKLMNATP53ITGA1PFKFB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818651-B2 ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors ALTANA PHARMA AG (DE) 2004-03-04 US disclosed
EP-1337515-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2003-08-27 EP disclosed
WO-2002040450-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS ALTANA PHARMA AG (DE) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors PDE7B, PDE3B, PDE3A GSPT1 1717/4885DDB1 1589/4885CRBN 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.